MXPA03006215A - Un proceso mejorado para preparar clorhidrato de ondansetron dihidratado puro. - Google Patents

Un proceso mejorado para preparar clorhidrato de ondansetron dihidratado puro.

Info

Publication number
MXPA03006215A
MXPA03006215A MXPA03006215A MXPA03006215A MXPA03006215A MX PA03006215 A MXPA03006215 A MX PA03006215A MX PA03006215 A MXPA03006215 A MX PA03006215A MX PA03006215 A MXPA03006215 A MX PA03006215A MX PA03006215 A MXPA03006215 A MX PA03006215A
Authority
MX
Mexico
Prior art keywords
ondansetron
process according
solution
hydrochloride
dihydrate
Prior art date
Application number
MXPA03006215A
Other languages
English (en)
Spanish (es)
Inventor
Bachar Eliezer
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of MXPA03006215A publication Critical patent/MXPA03006215A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56Ring systems containing three or more rings
    • C07D209/80[b, c]- or [b, d]-condensed
    • C07D209/82Carbazoles; Hydrogenated carbazoles
    • C07D209/86Carbazoles; Hydrogenated carbazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56Ring systems containing three or more rings
    • C07D209/80[b, c]- or [b, d]-condensed
    • C07D209/82Carbazoles; Hydrogenated carbazoles
    • C07D209/88Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Otolaryngology (AREA)
  • Anesthesiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
MXPA03006215A 2001-01-11 2002-01-11 Un proceso mejorado para preparar clorhidrato de ondansetron dihidratado puro. MXPA03006215A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26105201P 2001-01-11 2001-01-11
PCT/US2002/000853 WO2002055492A2 (en) 2001-01-11 2002-01-11 An improved process for preparing pure ondansetron hydrochloride dihydrate

Publications (1)

Publication Number Publication Date
MXPA03006215A true MXPA03006215A (es) 2005-02-17

Family

ID=22991757

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03006215A MXPA03006215A (es) 2001-01-11 2002-01-11 Un proceso mejorado para preparar clorhidrato de ondansetron dihidratado puro.

Country Status (21)

Country Link
EP (1) EP1355881A4 (ja)
JP (1) JP2004526692A (ja)
KR (3) KR20060113792A (ja)
CN (2) CN101045704A (ja)
AU (1) AU2002236753B2 (ja)
CA (1) CA2433720A1 (ja)
CZ (1) CZ20032090A3 (ja)
DE (1) DE02703115T1 (ja)
ES (1) ES2219201T1 (ja)
HR (1) HRP20030631A2 (ja)
HU (1) HUP0400767A2 (ja)
IL (1) IL156835A0 (ja)
IS (1) IS6869A (ja)
MX (1) MXPA03006215A (ja)
NO (1) NO20033147L (ja)
PL (1) PL368837A1 (ja)
SK (1) SK9892003A3 (ja)
TR (1) TR200401460T3 (ja)
WO (1) WO2002055492A2 (ja)
YU (1) YU56103A (ja)
ZA (1) ZA200305338B (ja)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7098345B2 (en) 2002-04-29 2006-08-29 TEVA Gyógyszergyár Zárkörüen Müködö Részvénytársaság Process for preparing 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-YL)methyl]-4H-carbazol-4-one
HU225885B1 (en) * 2002-10-17 2007-11-28 Richter Gedeon Nyrt Process for producing ondansetron hydrochlorid dihydrate of high purity
FI6164U1 (fi) * 2003-01-09 2004-03-15 Synthon Bv Ondansetronmuotoja
GB2398071B (en) * 2003-01-24 2006-06-07 Synthon Bv Process for making ondansetron and intermediate thereof
US7696356B2 (en) 2004-08-17 2010-04-13 Taro Pharmaceutical Industries Limited Process for preparing 1,2,3,9-tetrahydro-9-methyl-3-methylene-4H-carbazol-4-one and ondansetron therefrom
US7547791B2 (en) * 2004-10-26 2009-06-16 Ipca Laboratories Ltd. One-pot process for the preparation of antiemetic agent, 1,2,3,9-tetrahydro-9-methyl-3[(2-methyl)-1H-imidazole-1-yl)methyl]-4H-carbazol-4-O

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4695578A (en) * 1984-01-25 1987-09-22 Glaxo Group Limited 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances
GB8630071D0 (en) * 1986-12-17 1987-01-28 Glaxo Group Ltd Medicaments
CN1498216A (zh) * 2000-10-30 2004-05-19 ������ҩ��ҵ���޹�˾ 新的奥丹西隆盐酸盐晶体和溶剂化物及其制备方法

Also Published As

Publication number Publication date
JP2004526692A (ja) 2004-09-02
TR200401460T3 (ja) 2004-08-23
SK9892003A3 (en) 2004-05-04
CZ20032090A3 (cs) 2004-08-18
EP1355881A2 (en) 2003-10-29
KR20070054749A (ko) 2007-05-29
IS6869A (is) 2003-07-08
DE02703115T1 (de) 2004-10-21
KR20060113792A (ko) 2006-11-02
CN101045704A (zh) 2007-10-03
YU56103A (sh) 2006-05-25
KR20030068583A (ko) 2003-08-21
HRP20030631A2 (en) 2005-06-30
NO20033147D0 (no) 2003-07-09
ZA200305338B (en) 2004-07-12
PL368837A1 (en) 2005-04-04
WO2002055492A2 (en) 2002-07-18
HUP0400767A2 (hu) 2004-07-28
WO2002055492A3 (en) 2003-02-13
IL156835A0 (en) 2004-02-08
CA2433720A1 (en) 2002-07-18
ES2219201T1 (es) 2004-12-01
AU2002236753B2 (en) 2007-06-28
NO20033147L (no) 2003-09-02
EP1355881A4 (en) 2004-03-31
CN1496350A (zh) 2004-05-12

Similar Documents

Publication Publication Date Title
CN101547892B (zh) 制备(r)-8-氯-1-甲基-2,3,4,5-四氢-1h-3-苯并氮杂卓的方法和其中间体
US8501935B2 (en) Processes for the preparation of 8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine and intermediates related thereto
WO2007110761A2 (en) Polymorphic forms of olopatadine hydrochloride and methods for producing olopatadine and salts thereof
CN111630049B (zh) 用于制备2-(5-甲氧基异色满-1-基)-4,5-二氢-1h-咪唑及其硫酸氢盐的方法
US20090062534A1 (en) Linezolid crystalline hydrate form and linezolid salts
US9428442B2 (en) Process for the preparation of Clomiphene
EP2872499A1 (en) Process for the preparation of intermediates for the synthesis of dabigatran etexilate, and crystalline forms of said intermediates
MXPA03006215A (es) Un proceso mejorado para preparar clorhidrato de ondansetron dihidratado puro.
US5877351A (en) Preparation and purification process for 2- (dimethylamino) methyl!-1-(3-methoxphenyl)-cyclohexanol and its salts
AU2002236753A1 (en) An improved process for preparing pure ondansetron hydrochloride dihydrate
US20020115707A1 (en) Process for preparing pure ondansetron hydrochloride dihydrate
NO126371B (ja)
CN112979555B (zh) 一种合成西咪替丁的工艺
EP3015454A1 (en) Stable solid form of trans-Clomiphene citrate
EP2072510A1 (en) Crystalline form of azelastine
WO2020016827A1 (en) Purified crystalline detomidine hydrochloride monohydrate, anhydrate and free base with low amounts of iso-detomidine and other impurities by recrystallisation in water
EP2657232A2 (en) Process for the purification of a benzenesulphonamide compound
JPS61148173A (ja) 新規なアミン及びその塩
HUT56050A (en) Process for resolving 2-amino-4phenyl-butane
CN113754643A (zh) 苯并吡喃衍生物的精制方法、其晶型及所述晶型的制备方法
WO2006046253A1 (en) A one-pot process for the preparation of antiemetic agent, 1,2,3,9-tetrahydro-9-methyl-3[(2-methyl)-1h-imidazole-1-yl)methyl]-4h-carbazol-4-o
CN110885315A (zh) 左西孟旦药重要中间体的制备方法
CN115028582A (zh) 一种n-芳基吡唑类药物e-52862的制备方法及其产品
KR100342919B1 (ko) 트랜스체 염산 트라마돌의 분리 제조방법
EP3759081A1 (en) An improved process for the preparation of propiomazine maleate